Page last updated: 2024-11-03

proglumetacin and Idiopathic Parkinson Disease

proglumetacin has been researched along with Idiopathic Parkinson Disease in 1 studies

proglumetacin : A carboxylic ester obtained by formal condensation of the carboxy group of indometacin with the hydroxy group of 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl N(2)-benzoyl-N,N-dipropyl-alpha-glutaminate. Used (as its dimaleate salt) to control pain and inflammation associated with musculoskeletal and joint disorders. Following oral administration, it is metabolised to indometacin and proglumide, a drug with antisecretory effects that helps prevent injury to the stomach lining.

Research Excerpts

ExcerptRelevanceReference
"Twenty-nine patients with gouty arthritis, rheumatoid arthritis and osteoarthritis were treated as outpatients with proglumetacin, at different doses, during 5-30 days."3.66[Proglumetacin for a wide spectrum of activity in clinical medicine]. ( Fossaluzza, V, 1983)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fossaluzza, V1

Other Studies

1 other study available for proglumetacin and Idiopathic Parkinson Disease

ArticleYear
[Proglumetacin for a wide spectrum of activity in clinical medicine].
    Minerva medica, 1983, Jun-23, Volume: 74, Issue:26

    Topics: Adult; Aged; Arthritis, Rheumatoid; Diabetes Complications; Drug Tolerance; Female; Gout; Humans; In

1983